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LC-MS/MSBackground: Few pharmacokinetic data of acamprosate were available in Chinese population and nomedication
is approved for alcohol dependence in China.
Purpose: 1. Investigate the pharmacokinetic properties of acamprosate calcium in healthy Chinese male volun-
teers on single- and multiple-dose administration. 2. Compare the bioequivalence of two formulations of
acamprosate calcium tablets both under fasting and fed conditions.
Methods: This open-label, randomized study included 3 stages. In each stage, a 2-way crossover bioequivalence
study was conducted to study the pharmacokinetic properties and bioequivalence of acamprosate calcium tablets
onmultiple dosing after standardizedmeals, single dosing under fasting conditions and fed conditions, respectively.
The washout period between each treatment in a stage and between each stage was 1 week. Plasma acamprosate
calcium was quantiﬁed by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
Tolerability was evaluated by monitoring adverse events, physical examinations, 12-lead ECG, and laboratory tests.
Results: Totally, 36 male subjects were enrolled in the study and all of them completed the whole 3 study stages.
Main pharmacokinetic parameters of test and reference formulations were as follows: multiple dosing, Tmax
9.94 ± 6.59 and 9.47 ± 5.47 h, Cmax 435.74 ± 348.10 and 346.54 ± 155.66 ng · mL
−1, AUC0-t 8600.52 ±
5264.77 and 9315.10 ± 6820.03 ng · mL−1 · h, AUC0–∞ 8845.38 ± 5838.18 and 9669.24 ±
7326.53 ng · mL−1 · h, t1/2 10.06 ± 8.83 and 9.87 ± 10.35 h; single dosing under fasting conditions, Tmax 7.29 ±
4.87 and 6.57 ± 1.85 h, Cmax 247.85 ± 110.05 and 244.64 ± 132.43 ng · mL−1, AUC0-t 3385.41 ± 1418.92 and
3496.24 ± 1767.29 ng · mL−1 · h, AUC0–∞ 3781.53 ± 1556.96 and 3829.56 ± 1981.25 ng · mL
−1 · h, t1/2
13.07 ± 17.24 and 10.26 ± 7.78 h; single dosing under fed conditions, Tmax 17.72 ± 9.42 and 19.50 ± 9.84 h,
Cmax 183.90 ± 74.52 and 168.14 ± 60.67 ng · mL−1, AUC0-t 3181.71 ± 1368.24 and 3575.11 ±
1416.39 ng · mL−1 · h, AUC0–∞3442.39 ± 2002.53 and 3624.44 ± 1418.12 ng · mL
−1 · h, t1/2 8.76 ± 12.28 and
6.67±4.84 h, respectively. In all three stages, 90% CIs for the test/reference ratio of AUC0–t and AUC0–∞were located
within 80%–125%, 90% CI for Cmax was within 70%–143%.
Conclusions: Similar pharmacokinetic results of acamprosate calcium tablets in healthy Chinese volunteers were
found as those in Caucasic population. In all three stages, the two formulations met the regulatory criteria for
bioequivalence.
Chictr.org identiﬁer: ChiCTR-TTRCC-14004853.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alcohol dependence is a severe problem worldwide. According to
the World Health Organization, approximately 4% of all deaths in the
world are caused by alcohol abuse (World Health Organization, 2011).
In the United States, estimates of alcohol dependence is reported to be
12.5% and the price of the health care resulting from alcohol abuse is es-
timated at more than US$ 26 billion per year (Wright andMyrick, 2006;rk.
. This is an open access article underSaivin et al., 1998). In China, the rate of alcohol dependence is 3.7% in
1992, equivalent to approximately 50 million and the prevalence is in-
creasing (Hao et al., 2004). However, by now, nomedication is approved
in China for alcohol dependence (Tang et al., 2012). Acamprosate is the
newest approved drug in the United States for treatment of alcohol de-
pendence. It is structurally similar to gamma-aminobutyric acid (GABA)
and the inhibition of neuronal hyperexcitability mediated by antago-
nism ormodulation of activity at the NMDA receptor may be one expla-
nation of mechanism of action (Wright and Myrick, 2006; Saivin et al.,
1998; Scott et al., 2005).
Acamprosate tablets have been in clinical use formore than 10 years
for the indication of maintaining abstinence in alcohol-dependentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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kinetic characteristics of acamprosate calcium have been studied previ-
ously (Saivin et al., 1998), few data in Chinese population were
published.
The present study aimed to 1. Investigate the pharmacokinetic prop-
erties of acamprosate calcium in healthy Chinese male volunteers on
single- and multiple-dose administration. 2. Compare the bioequiva-
lence of two formulations of acamprosate calcium tablets both under
fasting and fed conditions. This was a registered study approved by
China Food and Drug Administration.
2. Subjects and Methods
2.1. Study Design and Drug Administration
This open-label, randomized study planning to enroll 36 healthy
male Chinese subjects included 3 stages. In each stage, a 2-way cross-
over bioequivalence studywas conducted. Thewashout period between
each treatment in a stage and between each stage was 1 week. Fig. 1
shows the ﬂowchart of the whole study.
In the ﬁrst stage, each subject received test or reference formulation
of 666 mg acamprosate calcium tablets randomly, three times per day
(7:30AM, 1:30 PM, and7:30 PM) after standardizedmeals (total energy
~900 calories; 30% protein, 60% carbohydrate, 10% fat) till the 8th day
morning. In the second stage, each subject received single dose of test
or reference formulation of 666 mg acamprosate calcium tablets ran-
domly, under fasting conditions (overnight fast for 12 h). In the third
stage, each subject received single dose of test or reference formulation
of 666 mg acamprosate calcium tablets randomly, under fed conditions
(high-fat, high-calorie; total energy 1000 calories, 60% fat, 15% protein,
25% carbohydrate). The study drug was administered with 200 mL
water. Additional water intake was permitted 2 h after dosing.
2.2. Study Population
Healthymale Chinese volunteers aged from18 to 40 andwith a body
mass index between 19 and 24 kg/m2were eligible for recruitment. Ad-
ditional inclusion criteria included a healthy status conﬁrmed by medi-
cal history, physical examination, 12-lead ECG, and laboratory tests
(hematology, blood biochemistry, hepatic function, urinalysis, hepatitis
B surface antigen, tests for alcohol and other drugs of abuse) and non-
smoking status. Thosewith any allergic history or history of cardiac, pul-
monary, renal, hepatic, gastrointestinal, or hematologic abnormality or
any other acute or chronic disease were excluded.
The study protocol was approved by the Independent Ethics Com-
mittee of West China Hospital, Sichuan University (Chengdu, China).
All subjects provided written informed consent.
2.3. Formulations
Acamprosate calcium enteric-coated tablets (CAMPRAL®, 333 mg;
lot no. A174451, A206998; expiration date May 2013) purchased from
Merck Santé s.a.s. and acamprosate calcium enteric-coated tabletsFig. 1. Flowchart of the study. (The washout period = 1 we(333 mg; lot no. 120401; expiration date Mar 2014) manufactured by
Kelun Pharmaceuticals Co. Ltd.(Sichuan, People's Republic of China)
were used as the reference and test formulations, respectively.
2.4. Sampling and Medical Supervision
Blood samples (~1.5 mL) were collected before and at 3, 4, 6, 8, 10,
12, 14, 16, 20, 24, 30, 36, 42, 48, 54, 60, 72, and 84 h after dosing in
the third stage and last dosing of the ﬁrst stage. At 7:30 AM and
7:30 PM on the 6th and 7th day of multiple-dosing stage, predose sam-
ples were collected to check the trough level. In the second stage, blood
samples were collected before and at 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 32,
40, 48, 60, 72, and 84 h after dosing. Fig. 2 shows the administration and
dosing schedule of one period in stage 1.
The subjects were under continuous medical supervision in the
Phase I Unit of West China Hospital, Sichuan University, throughout
the study. Tolerability was evaluated by monitoring adverse events,
physical examinations, 12-lead ECG, and laboratory tests. All laboratory
tests were performed at the laboratory of West China Hospital, Sichuan
University, which was authenticated by College of American Patholo-
gists (CAP).
2.5. Assays of Acamprosate Calcium
Plasma acamprosate calcium was quantiﬁed by a liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method de-
veloped and validated before the clinical study. API 3000 LC-MS/MS sys-
tem and Gemini C18 analysis column (4.6 × 4.0 mm, 5 μm) were used.
The protein of 150 μl plasma samplewas precipitatedwith 500 μl aceto-
nitrile. After evaporation of the supernatant, the residue was dissolved
in 100 μl mobile phase, washed with 1.0 ml dichloromethane, and
injected (15 μl) onto the column. The mobile phase of acetonitrile-
0.2% ammonium water(10:90, v:v, adjusted pH 4.0 with formic acid)
was pumped at 0.4 ml.min−1 through the column. Acetylate taurine
calcium was internal standard (IS). Transitions for multiple reaction
monitoring (MRM) were at m/z 180.2 → 79.9 and 166.1 → 79.9 for
acamprosate calcium and IS, respectively. The MS parameters were op-
timized for the detection: curtain gas 7, ion spray voltage −4500 V,
source temperature 500 °C, nebulizer gas 8, declustering potential
−75V, collision energy−35V, FP−70V, entrance potential−7 V, col-
lision cell exit potential−11.6 V. Typical chromatograms are shown in
Fig. 3. The retention time for acamprosate calcium and ISwere 2.73min
and 2.72 min, respectively. The calibration curve was linear over the
range of 2.0–1000 ng · mL−1. The limit of quantiﬁcation (LOQ) in plas-
ma was 2.0 ng · mL−1. The method recovery was 96%–114%; the intra-
day RSD less than 5% and inter-day RSD less than 9%. Matrixes effect of
acamprosate calcium was below 11%. The results of all stability studies
were ﬁt for requirement.
2.6. Pharmacokinetics and Bioequivalence Analysis
Pharmacokinetic parameters of acamprosate calcium were calculat-
edwithWinNonlin Version 6.1 (Pharsight Corporation, Mountain View,ek; T = Test formulation; R = Reference formulation.)
Fig. 2. Administration and dosing schedule of one period in stage 1.
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obtained directly from the concentration–time data. AUC0–t was calcu-
lated using the linear trapezoidal rule. AUC0–∞ was calculated as the
sum of AUC0–t and Ct/λ. Ctwas the last measured concentration and λ
was the slope of linear regression of the log-transformed concentra-
tion–time curve, and t1/2 was calculated as 0.693/λ.
The relative bioavailability of the test formulation was calculated as
F = AUC0–t(test)/AUC0–t(reference) × 100%. 90% CIs for the test/reference
ratio of log-transformed Cmax and AUC were evaluated by analysis of
variance (ANOVA) using WinNonlin Version 6.1. Tmax was tested by
paired Wilcoxon test for signiﬁcant differences. According to China Food
and Drug Administration proposal, the formulations were considered to
be bioequivalent if the 90% CI for AUC was located within 80%–125%
and Cmax within 70%–143% (State Food and Drug Administration, n.d.).
Other pharmacokinetic parameters were analyzed using SPSS Ver-
sion 18.0 (SPSS Inc. Chicago, IL, USA). The paired T-test or paired
Wilcoxon test was used to determine signiﬁcant differences. For all
the analyses, P b 0.05 was considered as statistically signiﬁcant.Fig. 3. LC-MS/MS of acamprosate of blank plasma solution (A), reference standards solution (3. Results
3.1. Study Population
We totally enrolled 36 male subjects and all of them completed the
whole study. The demographic details (mean ± SD) were age 22.1 ±
1.6 years, weight 60.9 ± 5.7 kg, height 1.70 ± 0.05 cm, body mass
index 21.0 ± 1.2 kg/m2.3.2. Pharmacokinetic Properties
The detailed pharmacokinetic parameters of the two formulations of
acamprosate calcium tablets on multiple dosing after standardized
meals, single dosing under fasting conditions and fed conditions
are presented in Table 1. The mean plasma acamprosate calcium con-
centration–time curves of test and reference formulations are shown
in Fig. 4.B), blank plasma with reference standards solution (C), and subject plasma solution(D).
Table 1
Pharmacokinetic parameters of two formulations of acamprosate calcium tablets onmultiple dosing after standardizedmeals, single dosing under fasting conditions and fed conditions in
healthy Chinese volunteers. All values are mean ± SD (n = 36).
PK parameter Multiple dosing Single dosing (fasting conditions) Single dosing (fed conditions)
Test Reference Test Reference Test Reference
Tmax, h 9.94 ± 6.59 9.47 ± 5.47 7.29 ± 4.87 6.57 ± 1.85 17.72 ± 9.42 19.50 ± 9.84
Cmax, ng · mL−1 435.74 ± 348.10 346.54 ± 155.66 247.85 ± 110.05 244.64 ± 132.43 183.90 ± 74.52 168.14 ± 60.67
AUC0-t, ng · mL−1 · h 8600.52 ± 5264.77 9315.10 ± 6820.03 3385.41 ± 1418.92 3496.24 ± 1767.29 3181.71 ± 1368.24 3575.11 ± 1416.39
AUC0–∞, ng · mL−1 · h 8845.38 ± 5838.18 9669.24 ± 7326.53 3781.53 ± 1556.96 3829.56 ± 1981.25 3442.39 ± 2002.53 3624.44 ± 1418.12
t1/2, h 10.06 ± 8.83 9.87 ± 10.35 13.07 ± 17.24 10.26 ± 7.78 8.76 ± 12.28 6.67 ± 4.84
MRT0–t, h 18.19 ± 6.10 17.92 ± 6.44 16.80 ± 5.74 16.77 ± 6.41 25.21 ± 9.06 26.26 ± 8.11
Cmin, ng · mL−1 211.48 ± 110.03 222.87 ± 148.72 \\ \\ \\ \\
Cavg, ng · mL−1 294.48 ± 154.91 293.25 ± 154.01 \\ \\ \\ \\
V/F, L 1364.02 ± 1210.64 1239.11 ± 1050.95 2773.04 ± 2066.18 2818.69 ± 2009.58 2308.73 ± 1595.85 2141.96 ± 1976.71
Cl/F, L/h 102.65 ± 54.87 107.81 ± 74.86 198.94 ± 72.97 221.16 ± 111.64 239.82 ± 108.12 220.08 ± 107.43
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The 90% CIs for the test/reference ratio of log-transformed Cmax,
AUC0–t, AUC0–∞ were shown in Table 2. In all three stages, 90% CIs ofFig. 4. Mean plasma concentration–time curves of test and reference formulations of
acamprosate calcium tablets on multiple dosing after standardized meals (A), single
dosing under fasting conditions (B) and fed conditions (C).AUC0–t and AUC0–∞ were located within 80%–125%, 90% CI for Cmax
waswithin 70%–143%. The two formulationswere considered to be bio-
equivalent on multiple dosing, single dosing under fasting conditions
and fed conditions.
3.4. Tolerability
Among the 36 subjects, 3 of them reported looser stools, which hap-
pened during the multiple-dosing stage, both after administration of
test and reference formulations. One subject reported abdominal pain
after administration of test formulation during the multiple-dosing
stage. One subject reported skin rash after administration of reference
formulation during themultiple-dosing stage. The above adverse events
were rated as mild and considered possibly associated with the study
drug. No other adverse events were observed or reported. Physical ex-
amination, electrocardiograms, and laboratory tests did not suggest
any clinically signiﬁcant abnormality.
4. Discussion
Although acamprosate has been clinically used for decades, few data
on the pharmacokinetic properties of acamprosate were openly pub-
lished. To our knowledge, the pharmacokinetic data of acamprosate
were mainly based on the internal reports of Lipha company, which
have been reviewed previously (Saivin et al., 1998). The present study
investigated the pharmacokinetic properties of acamprosate calcium
in healthy Chinese male volunteers on single- and multiple-dose ad-
ministration and compared the bioequivalence of two formulations of
acamprosate calcium tablets both under fasting and fed conditions.
Acamprosate is available in 333 mg enteric-coated tablets and the
recommended dosage is two 333 mg tablets taken orally three times
daily (Lipha, 1995). After oral administration, acamprosate is poorly
absorbed, with an average bioavailability of about 11% under fasting
conditions (Fourtillan, 1990). Considering the pharmacokinetic proper-
ties and dosage form of tested formulations (EuropeanMedicines Agen-
cy, n.d.; FDA Guidance for Industry: Food-Effect Bioavailability and Fed
Bioequivalence Studies, 2002), we designed this 3-stage study to evalu-
ate the PK properties and bioequivalence of acamprosate calcium tab-
lets under different conditions.
Previous studies indicated that after administration of single oral
dose of 666 mg acamprosate calcium tablets in healthy volunteers,
Cmax ranged from 162 ± 22 to 212 ± 83 ng · mL−1, AUC0–∞ from
1988 ± 431 to 4110 ± 442 ng · mL−1 · h, and Tmax was between
4.3 ± 1.2 and 15.3 ± 2.2 h (Saivin et al., 1998; Fourtillan, 1992;
Sennesael, 1992; Dewland, 1995). After multiple-dose administration,
Steady-state plasma concentrations of acamprosatewere reachedwith-
in 5 days, ranging from 370 ± 145 to 644 ± 386 ng · mL−1.
Acamprosate is not metabolized in the liver and approximately 90% of
the drug is excreted unchanged in the urine. The terminal half-life
ranges from 13.0 to 32.7 h after oral dosing of 666 mg of acamprosate
calcium tablets (Saivin et al., 1998; Fourtillan, 1992; Sennesael, 1992;
Table 2
Bioequivalence evaluation of two formulations of acamprosate calcium tablets in healthy Chinese volunteers (n = 36).
Multiple dosing Single dosing (fasting conditions) Single dosing (fed conditions)
Test/reference ratio 90% CI Test/reference ratio 90% CI Test/reference ratio 90% CI
AUC0–t 98.85% 85.19%–113.70% 102.99% 91.27%–116.22% 89.19% 80.76%–98.49%
AUC0− ∞ 98.30% 84.49%–113.96% 105.84% 92.36%–121.29% 91.97% 82.73%–102.24%
Cmax 115.26% 97.91%–135.69% 103.94% 92.41%–116.9% 108.57% 96.11%–122.63%
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ma concentrations was reached around the 5th day of multiple dosing,
which accordedwith the previous studies. Other pharmacokinetic prop-
erties, including Cmax, AUC, Tmax, and t1/2 were in the same range as in
the previously reported studies (Saivin et al., 1998; Fourtillan, 1992;
Sennesael, 1992; Dewland, 1995). Our study showed that the accumula-
tion ratio between day 8 and 1 was 2.48 in test formulation and 2.66 in
reference formulation, both corroborating the earlier results (Pelc,
1993). The present study indicated similar pharmacokinetic results of
acamprosate calcium tablets in healthy Chinese volunteers as those
found in Caucasic population.
Previous studies indicated that co-administration of acamprosate
with fooddecreases bioavailability asmeasured by Cmax andAUC, by ap-
proximately 42% and 23%, respectively, while Tmax was not signiﬁcantly
modiﬁed (Fourtillan, 1992). However, the food effect on absorption is
not clinically signiﬁcant and no adjustment of dose is necessary
(Saivin et al., 1998; Lipha, 1995). In the present study, Cmax of both
test and reference formulations were decreased by 25%–30% in accor-
dance to previous studies. However, our study indicated that Tmax
were prolonged from 7.29 to 17.72 h (test formulation) and 6.57
to 19.50 h (reference formulation) under fed conditions compared
with those under fasting conditions. Furthermore, AUC were not
signiﬁcantlymodiﬁed. The possible reason of such discordance between
results might be the food conditions of the test meals. In the previous
study, standard meals (total energy 900 calories; 30% protein, 60%
carbohydrate, 10% fat) were used; however, in the present study,
we used high-fat, high-calorie meals (total energy 1000 calories,
60% fat, 15% protein, 25% carbohydrate). Our study suggested that the
food effect on acamprosate absorption may be inﬂuenced by food
conditions.
In the present study, double-peak phenomenonwas observed in the
concentration–time curves of many subjects, especially under fed con-
ditions. The double-peak phenomenon may be attributed to the formu-
lation being enteric coated and multiple absorption sites in the gut. The
tested enteric-coated tablets formulations in the present study could be
absorbed in multiple sites, including duodenum, jejunum, and ileum.
Furthermore, as discussed above, the mean time to reach maximum
plasma drug concentration was prolonged under fed conditions, sug-
gesting that high-fat, high-calorie meals could delay gastic emptying
of acamprosate, whichmade the double-peak phenomenonmore obvi-
ous. In two previous pharmacokinetic studies of acamprosate solution
formulation (Dewland, 1991; Fourtillan, 1989), no double-peak phe-
nomenon was observed, which suggested that enterohepatic recycling
may be ruled out for the reasons of double-peak phenomenon. In previ-
ously reported data of acamprosate enteric-coated tablets, double-peak
phenomenon was observed in Caucasian people, too (Fourtillan, 1990).
In a study byAnders etc. in 2010 (Hammarberg et al., 2010), an LC-MS
method was used to examine the levels of acamprosate both in human
plasma and cerebrospinal ﬂuid (CSF). The calibration curve was linear
over the range of 50–1000 ng · mL−1 and the author estimated the
level of acamprosate in CSF to be between 9 and 33 ng/mL, which was
below the LOQ. In the present study, the use of LC-MS⁄MS appeared to
increase the sensitivity formeasurement. Furthermore,we used acetylate
taurine calcium as internal standard and increased the sensitivity as com-
pared with the previously reported methods (Rhee et al., 2008; Burattini
et al., 2008). The LOQ of the present method was 2.0 ng · mL−1. The
method validation results of speciﬁcity, precision, accuracy, recovery,and stability suggested that our method was suitable for the assay of
acamprosate in human plasma.
A limitation of the present study is that we did not examine the
levels acamprosate in the human central nervous system as the
above-mentioned study because we failed to get the approval of the
Ethics Committee about the sampling of cerebrospinal ﬂuid of subjects.
5. Conclusions
Similar pharmacokinetic results of acamprosate calcium tablets in
healthy Chinese volunteers were found as those in Caucasic population.
In all three stages, the two formulations met the regulatory criteria for
bioequivalence.
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